Meghan Joyce V

October 17, 2026

Guardant Health Wins Patent Ruling, Morgan Stanley Lifts Target. Guardant Health secured a favorable decision from the U.S. Patent Trial and Appeal Board, which rejected a challenge to its core duplex sequencing patent. This legal win supports the company's position in the growing liquid biopsy market. Additionally, Morgan Stanley maintained an Overweight rating and raised its price target to $200, citing strong fundamentals in the diagnostics sector.

October 13, 2026

Boston Beer (SAM) sees mixed premium push, analyst cuts target. Boston Beer continues its premiumization strategy, but recent commentary describes the results as mixed, noting both higher‑margin products and uncertain consumer response. The company is extending its lifestyle branding through a new Realtree Camo promotion for Twisted Tea, aiming to deepen market reach. RBC Capital kept its sector‑perform rating but lowered its price target to $190, reflecting a more cautious outlook.

October 5, 2026

Oscar Health Analyst Target Rises to $34.19. Analysts raised the consensus price target for Oscar Health by 12.09% to $34.19. This adjustment follows recent updates to the company's earnings roadmap and new product initiatives. The stock is currently trading near the upper end of its 52-week range, reflecting renewed interest in its growth prospects.